SELECT * FROM `tbl_content` WHERE `c_type` = 'advertise' AND `c_status` = '1' AND `c_is_deleted` = '0' ORDER BY `c_order` desc LIMIT 3 Association of Biotechnology Led Enterprises


"Happy New Year, All Risks Paid Off': Adar Poonawalla On Vaccine Approval

Covishield is ready for "roll-out in the coming weeks", said Adar Poonawalla

Jan 03, 2021


Bharat Biotech’s ‘COVAXIN™’ Emergency Use Authorization approval by DCGI-CDSCO, MoH&FW, a significant landmark in India’s Scientific Discovery, and Scientists Capability

Dr. Krishna Ella said “The approval of COVAXIN™ for emergency use is a giant leap for Innovation and novel product development in India. It is a proud moment for the nation and a great milestone in India’s scientific capability, a kickstart to the innovation ecosystem in India. While this vaccine addresses an unmet medical need during this pandemic, our goal is to provide global access to populations that need it the most. COVAXIN™ has generated excellent safety data with robust immune responses to multiple viral proteins that persist.”

Jan 03, 2021

By : Team ABLE

India’s biggest bio entrepreneurship platform, NBEC 2020 crowns 14 winners after an intense four-month-long competition

The winners in the student-team innovation category were Tanish T. Sridhar who won the Persistent Systems sponsored cash prize of 5 lakhs INR, Chandan Kumar Jha who won the BIRAC cash prize of 3 lakhs INR, and Abduljabbar Khan who won 2 lakhs INR in a pooled prize by K&S partners, Bioneeds and Ideaspring Capital.

Dec 19, 2020

By : C-Camp

Bangalore Bioinnovation Centre receives “Innovation Leadership Award”

Dr Jitendra Kumar, Managing Director of BBC said “It is an honour for team BBC to receive this award. It is great that the jury has looked into the institutions that have made the difference to the lives of others”

Dec 23, 2020

By : Team ABLE

COVAXIN phase 2 study results & Phase-1 follow Up data

COVAXIN™ (BBV152) showed long-term antibody and T-cell memory responses (3-months after vaccination) in phase 1 volunteers, and tolerable safety outcomes with enhanced humoral & cell-mediated immune responses in the Phase 2 study.

Dec 24, 2020

By : Team ABLE